Navigation Links
Vivakor Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation
Date:12/14/2009

CORALVILLE, Iowa, Dec. 14 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced the launch of its new website promoting its remarkable VivaThermic Vial at www.vivathermic.com. In addition to providing customers with the latest news and developments for its VivaThermic product line, Vivakor developed this site to be a valuable resource for its domestic and international customers, such as the highly respected Veritas Corporation of Tokyo, Japan, which signed an exclusive five year exclusive distribution agreement to distribute Vivakor's VivaThermic products in Japan. Under the terms of the Agreement, Veritas will have exclusive distribution rights to all Vivakor's VivaThermic Division products in Japan, including the recently released VivaThermic SUPER-150 and VivaThermic UTLRA-300 cryovials.

Mr. Shinsaku Iida, President of Veritas Corporation, stated: "As a leading distributor of a biotech products in Japan, including capital equipment, reagents, and kits to support research in the fields of genomics, proteomics, and metabolomics, we believe we are the perfect partner for Vivakor and their VivaThermic product line. In Japan, as in the rest of the world, there is a real need for better sample preparation methods that will allow for the safe, rapid, and reliable sample preservation from a variety of biomaterials. We are very impressed with new Ultra CryoVials, believe that it is the best system available for sample preservation, and believe that we will be very successful in placing the entire cryo-preservation system in the Japanese market as 21 century's gold standard."

Vivakor's CEO, Dr. Tannin Fuja, indicated that, "We are pleased to launch the VivaThermic website that will not only promote domestic distribution but assist our international distributors. We are also pleased to partner with the highly-respected Japanese corporation, Veritas, to distribute our superior VivaThermic products. The Japanese biotechnology industry is one of the leading participants in the global biotech market. Japan, with its family of industry leading biotechnology companies, continues to lead in this increasingly global market."

About Vivakor

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at www.vivakor.com.

About Veritas Corporation

Veritas is a trusted distributor of cutting edge products from around the world to the Japanese life science community. Established in 1972, Veritas is well known for superior technical support and knowledgeable sales and marketing staff. In addition to Vivakor's VivaThermic products, Veritas represents prestigious suppliers from USA, Canada, Germany, England, Sweden, Italy, New Zealand, China, and India for life science products. Veritas specializes in cell biology (including stem cell biology), immunology, hematology and microbiology, as well as to sophisticated scientific instruments and niche services.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.


    Contact:
    Vivakor Investor Relations
    c/o IME Advisors
    (888) 648-848

SOURCE Vivakor, Inc.


'/>"/>
SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vivakor Announces New Acquisition Strategy
2. Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customers Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders
3. Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer
4. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
5. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
6. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
7. RetireSafe Announces Intention to Key Vote Senator Dorgans Drug Importation Amendment (SA 2793)
8. Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign
9. Neogen Corporation Announces 2nd Quarter Results
10. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
11. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):